SCHEMBL5196202

SCHEMBL5196202

O=C(O)c1ccccc1C1CC=CC1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.50
ALOX15 P16050 1/20 0.50
CYP2C9 P11712 1/20 0.49
KDM4E B2RXH2 3/20 0.43
HPGD P15428 2/20 0.43
CA12 O43570 1/20 0.43
CA1 P00915 1/20 0.43
CA2 P00918 1/20 0.43
HMGB1 P09429 1/20 0.43
CA4 P22748 1/20 0.43
CA6 P23280 1/20 0.43
CA7 P43166 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
CA9 Q16790 1/20 0.43
NAPRT Q6XQN6 1/20 0.43
CA14 Q9ULX7 1/20 0.43
MAPT P10636 3/20 0.42
HDAC8 Q9BY41 1/20 0.42
AKR1C3 P42330 2/20 0.41
POLB P06746 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4357324 0.88 RAB9A (0.43) ALDH1A1ALOX15CYP2C9KDM4EHPGD
SCHEMBL4109572 0.83 ALDH1A1 (0.54) ALDH1A1ALOX15CYP2C9KDM4EHPGD
SCHEMBL30175300 0.83 ALDH1A1 (0.54) ALDH1A1ALOX15CYP2C9KDM4EHPGD
SCHEMBL10457353 0.83 ALDH1A1 (0.54) ALDH1A1ALOX15CYP2C9KDM4EHPGD
SCHEMBL8487411 0.83 TSHR (0.45) ALDH1A1ALOX15CYP2C9KDM4EHPGD
Hydrochloric Acid SCHEMBL29705669 0.82 ALDH1A1 (0.52) ALDH1A1ALOX15CYP2C9KDM4EHPGD
SCHEMBL21812120 0.81 CYP2C9 (0.41) ALDH1A1ALOX15CYP2C9KDM4EHPGD
SCHEMBL2731512 0.80 ALDH1A1 (0.50) ALDH1A1ALOX15CYP2C9KDM4EHPGD
SCHEMBL3634253 0.80 ALDH1A1 (0.50) ALDH1A1ALOX15CYP2C9KDM4EHPGD
SCHEMBL10878096 0.78 ALDH1A1 (0.48) ALDH1A1ALOX15CYP2C9KDM4EHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116323596-A Interleukin-17 inhibitors 诺华股份有限公司 2023-06-23 CN disclosed
EP-3019196-A1 COMBINATIONS OF HEPATITIS C VIRUS INHIBITORS Bristol-Myers Squibb Company (US) 2016-05-18 EP disclosed
WO-2015005901-A1 COMBINATIONS OF HEPATITIS C VIRUS INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2015-01-15 WO disclosed
EP-2802326-A1 HEPATITIS C VIRUS INHIBITORS Bristol-Myers Squibb Company (US) 2014-11-19 EP disclosed
WO-2013106520-A1 HEPATITIS C VIRUS INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2013-07-18 WO disclosed
EP-1805196-A1 SUBSTITUTED ADENINES AND THE USE THEREOF AstraZeneca AB (SE) 2007-07-11 EP disclosed
EP-1551821-B1 3-(CYCLOPENTEN-1-YL)-BENZYL- OR 3-(CYCLOPENTEN-1-YL)-HETEROARYLMETHYL-AMINE DERIVATIVES AND USE THEREOF AS MEDICINES FOR TREATING SCHIZOPHRENIA PF MEDICAMENT (FR) 2006-05-17 EP disclosed
WO-2006040558-A1 SUBSTITUTED ADENINES AND THE USE THEREOF ASTRAZENECA AB (SE) 2006-04-20 WO disclosed
EP-1551821-A1 3-(CYCLOPENTEN-1-YL)-BENZYL- OR 3-(CYCLOPENTEN-1-YL)-HETEROARYLMETHYL-AMINE DERIVATIVES AND USE THEREOF AS MEDICINES FOR TREATING SCHIZOPHRENIA PIERRE FABRE MEDICAMENT (FR) 2005-07-13 EP disclosed
WO-2004035561-A1 3-(CYCLOPENTEN-1-YL)-BENZYL- OR 3-(CYCLOPENTEN-1-YL)-HETEROARYLMETHYL-AMINE DERIVATIVES AND USE THEREOF AS MEDICINES FOR TREATING SCHIZOPHRENIA PIERRE FABRE MEDICAMENT (FR) 2004-04-29 WO disclosed